Stockreport

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed B.V.  (MYNZ) 
PDF 2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples [Read more]